Norovirus Bivalent (GI.1/GII.4) Vaccine
/ Beijing Zhongsheng Hengyi Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
October 28, 2022
Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)
(clinicaltrials.gov)
- P2 | N=1716 | Recruiting | Sponsor: National Vaccine and Serum Institute, China | Trial completion date: Sep 2023 ➔ Mar 2024 | Trial primary completion date: Jun 2022 ➔ Feb 2024
Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Infectious Disease
May 06, 2022
Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)
(clinicaltrials.gov)
- P2 | N=1716 | Recruiting | Sponsor: National Vaccine and Serum Institute, China | Trial primary completion date: Mar 2022 ➔ Jun 2022
Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Infectious Disease
July 06, 2021
Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)
(clinicaltrials.gov)
- P2; N=1716; Recruiting; Sponsor: National Vaccine and Serum Institute, China; Not yet recruiting ➔ Recruiting
Enrollment open • Gastroenterology • Gastrointestinal Disorder • Infectious Disease
June 28, 2021
Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)
(clinicaltrials.gov)
- P2; N=1716; Not yet recruiting; Sponsor: National Vaccine and Serum Institute, China
Clinical • New P2 trial • Gastroenterology • Gastrointestinal Disorder • Infectious Disease
April 22, 2021
A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine
(clinicaltrials.gov)
- P1; N=510; Completed; Sponsor: National Vaccine and Serum Institute, China; Recruiting ➔ Completed
Trial completion • Gastroenterology • Gastrointestinal Disorder • Infectious Disease
1 to 5
Of
5
Go to page
1